Cellectis (XPAR:ALCLS) Current Accrued Expense : €4.96 Mil (As of Mar. 2025)

View and export this data going back to 2007. Start your Free Trial

What is Cellectis Current Accrued Expense?

Cellectis's Current Accrued Expense for the quarter that ended in Mar. 2025 was €4.96 Mil.

Cellectis's quarterly Current Accrued Expense increased from Sep. 2024 (€7.39 Mil) to Dec. 2024 (€8.43 Mil) but then declined from Dec. 2024 (€8.43 Mil) to Mar. 2025 (€4.96 Mil).

Cellectis's annual Current Accrued Expense declined from Dec. 2022 (€8.89 Mil) to Dec. 2023 (€8.59 Mil) and declined from Dec. 2023 (€8.59 Mil) to Dec. 2024 (€8.43 Mil).

Cellectis Current Accrued Expense Historical Data

The historical data trend for Cellectis's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Current Accrued Expense Chart

Cellectis Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Current Accrued Expense

Get a 7-Day Free Trial

10.66

11.05

8.89

8.59

8.43

Cellectis Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Current Accrued Expense	Get a 7-Day Free Trial															5.26	6.47	7.39	8.43	4.96

Cellectis Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Cellectis Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Cellectis's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Cellectis Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (XPAR:ALCLS) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

CLLS:USA 0WA2:UK ZVAA:Germany

Address

8, rue de la Croix Jarry, Paris, FRA, 75013

Website

https://www.cellectis.com

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Cellectis Headlines

No Headlines